Free Access
Issue
Med Sci (Paris)
Volume 40, Novembre 2024
Les Cahiers de Myologie
Page(s) 6 - 8
Section Mise Au Point
DOI https://doi.org/10.1051/medsci/2024128
Published online 18 November 2024
  1. Axeen EJT, Olson HE. Neonatal epilepsy genetics. Semin Fetal Neonatal Med 2018 ; 23 : 197. [CrossRef] [PubMed] [Google Scholar]
  2. Krahn M, Biancalana V, Cerino M, et al. A national French consensus on gene lists for the diagnosis of myopathies using next-generation sequencing. Eur J Hum Genet 2019 ; 27 : 349. [CrossRef] [PubMed] [Google Scholar]
  3. Berg JS, Foreman AKM, O’Daniel JM, et al. A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing. Genet Med 2016 ; 18 : 467. [CrossRef] [PubMed] [Google Scholar]
  4. Vecten M, Pion E, Bartoli M, et al. Objective evaluation of clinical actionability for genes involved in myopathies: 63 genes with a medical value for patient care. Int J Mol Sci 2022 ; 23 : 8506. [CrossRef] [PubMed] [Google Scholar]
  5. Thompson R, Bonne G, Missier P, et al. Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a Treatabolome. Emerg Top Life Sci 2019 ; 3 : 19. [CrossRef] [PubMed] [Google Scholar]
  6. Bonne G. The Treatabolome, an emerging concept. J Neuromuscul Dis 2021 ; 8 (3) : 337–339. [CrossRef] [PubMed] [Google Scholar]
  7. Atalaia A, Thompson R, Corvo A, et al. A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome. Orphanet J Rare Dis 2020 ; 15 (1) : 206. [CrossRef] [PubMed] [Google Scholar]
  8. Atalaia A, Ben Yaou R, Wahbi K, et al. Laminopathies’ treatments systematic review: a contribution towards a ‘Treatabolome’. J Neuromuscul Dis 2021 ; 8 (3) : 419–439. [CrossRef] [PubMed] [Google Scholar]
  9. Desaphy JF, Altamura C, Vicart S, Fontaine B. Targeted therapies for skeletal muscle ion channelopathies: systematic review and steps towards precision medicine. J Neuromuscul Dis 2021 ; 8 (3) : 357–381. [CrossRef] [PubMed] [Google Scholar]
  10. Manta A, Spendiff S, Lochmüller H, Thompson R. Targeted therapies for metabolic myopathies related to glycogen storage and lipid metabolism: a systematic review and steps towards a ‘Treatabolome’. J Neuromuscul Dis 2021 ; 8 (3) : 401–417. [CrossRef] [PubMed] [Google Scholar]
  11. Tiet MY, Lin Z, Gao F, et al. Targeted therapies for Leigh syndrome: systematic review and steps towards a ‘Treatabolome’. J Neuromuscul Dis 2021 ; 8 (6) : 885–897. [CrossRef] [PubMed] [Google Scholar]
  12. Jennings MJ, Lochmüller A, Atalaia A, Horvath R. Targeted therapies for hereditary peripheral neuropathies: systematic review and steps towards a ‘Treatabolome’. J Neuromuscul Dis 2021 ; 8 (3) : 383–400. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.